SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-472929"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-472929" > Cytogenetics in Chr...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005241naa a2200541 4500
001oai:DiVA.org:uu-472929
003SwePub
008220422s2022 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:149214695
009oai:prod.swepub.kib.ki.se:235392482
009oai:prod.swepub.kib.ki.se:154844802
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4729292 URI
0247 a https://doi.org/10.1097/HS9.00000000000007072 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1492146952 URI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:2353924822 URI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1548448022 URI
040 a (SwePub)uud (SwePub)kid (SwePub)kid (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Baliakas, Panagiotis,d 1977-u Uppsala universitet,Science for Life Laboratory, SciLifeLab,Experimentell och klinisk onkologi,Uppsala Univ Hosp, Dept Clin Genet, Uppsala, Sweden.4 aut0 (Swepub:uu)panba345
2451 0a Cytogenetics in Chronic Lymphocytic Leukemia :b ERIC Perspectives and Recommendations
264 1b Ovid Technologies (Wolters Kluwer Health),c 2022
338 a electronic2 rdacarrier
520 a Mounting evidence underscores the clinical value of cytogenetic analysis in chronic lymphocytic leukemia (CLL), particularly as it allows the identification of complex karyotype, that has recently emerged as a prognostic and potentially predictive biomarker. That said, explicit recommendations regarding the methodology and clinical interpretation of either chromosome banding analysis (CBA) or chromosome microarray analysis (CMA) are still lacking. We herein present the consensus of the Cytogenetic Steering Scientific Committee of ERIC, the European Research Initiative on CLL, regarding methodological issues as well as clinical interpretation of CBA/CMA and discuss their relevance in CLL. ERIC considers CBA standardized and feasible for CLL on the condition that standards are met, extending from the use of novel mitogens to the accurate interpretation of the findings. On the other hand, CMA, is also standardized, however, robust data on its clinical utility are still scarce. In conclusion, cytogenetic analysis is not yet mature enough to guide treatment choices in CLL. That notwithstanding, ERIC encourages the wide application of CBA, and potentially also CMA, in clinical trials in order to obtain robust evidence regarding the predictive value of specific cytogenetic profiles towards refining risk stratification and improving the management of patients with CLL.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
7001 a Espinet, Blancau Hosp del Mar, Mol Cytogenet Lab, Pathol Dept, Barcelona, Spain.;Inst Hosp del Mar Invest Med IMIM, Canc Res Program, Translat Res Hematol Neoplasms Grp, Barcelona, Spain.4 aut
7001 a Mellink, Clemensu Univ Amsterdam, Amsterdam Univ Med Ctr, Dept Clin Genet, Genom Lab, Amsterdam, Netherlands.4 aut
7001 a Jarosova, Marieu Masaryk Univ, Fac Med, Inst Med Genet & Genom, Brno, Czech Republic.;Univ Hosp Brno, Brno, Czech Republic.;Masaryk Univ, Univ Hosp Brno, Dept Internal Med Hematol & Oncol, Brno, Czech Republic.;Masaryk Univ, Fac Med, Brno, Czech Republic.4 aut
7001 a Athanasiadou, Anastasiau G Papanicolaou Hosp, Hematol Dept, Thessaloniki, Greece.;G Papanicolaou Hosp, HCT Unit, Thessaloniki, Greece.4 aut
7001 a Ghia, Paolou IRCCS Osped San Raffaele, Div Expt Oncol, CLL & BCell Neoplasia Unit, Strateg Res Program, Milan, Italy.;Univ Vita Salute San Raffaele, Milan, Italy.4 aut
7001 a Kater, Arnon P.u Univ Amsterdam, Amsterdam Univ Med Ctr, Lymphoma & Myeloma Ctr Amsterdam, Dept Hematol,Canc Ctr Amsterdam, Amsterdam, Netherlands.4 aut
7001 a Oscier, Davidu Royal Bournemouth Hosp, Dept Haematol, Bournemouth, Dorset, England.4 aut
7001 a Haferlach, Claudiau MLL Munich Leukemia Lab, Munich, Germany.4 aut
7001 a Stamatopoulos, Kostasu Karolinska Institutet4 aut
7102 a Uppsala universitetb Science for Life Laboratory, SciLifeLab4 org
7730 t HemaSphered : Ovid Technologies (Wolters Kluwer Health)g 6:4q 6:4x 2572-9241
8564 u https://doi.org/10.1097/HS9.0000000000000707y Fulltext
8564 u https://uu.diva-portal.org/smash/get/diva2:1653481/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-472929
8564 8u https://doi.org/10.1097/HS9.0000000000000707
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:149214695
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:235392482
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:154844802

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy